Thus, we examined the synergistic effect of the combination of asciminib and imatinib in BCR‐ABL inhibitor‐resistant CML and examined the mechanism of the synergistic effect. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.